Eiger Mountains

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020
PALO ALTO, Calif. , May 29, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and
View HTML
Toggle Summary Eiger to Present at Jefferies Virtual Healthcare Conference 2020
PALO ALTO, Calif. , May 26, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
PALO ALTO, Calif. , May 19, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
PALO ALTO, Calif. , May 7, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update.
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
- Six International, Investigator Sponsored Studies Initiating and Enrolling PALO ALTO, Calif. , April 30, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies
- Accelerated Assessment of MAA Previously Granted by EMA in March PALO ALTO, Calif. , April 27, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that
View HTML
Toggle Summary Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
- HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline - Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating PALO ALTO, Calif. , April 1, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR ), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif., March 23, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA - Progeria NDA Submission Complete by End of March 2020 - Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif. , March 13, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
- Launch Preparation Underway for Lonafarnib in Progeria - Market Development Activities Advancing for HDV Program PALO ALTO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and
View HTML
Toggle Summary Eiger Updates on 2019 Progress and 2020 Milestones Expected
- Progeria Rolling NDA Planned for Completion in 1Q 2020 - HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 - Commercial Focus on Progeria Launch Preparation and HDV Market Building - Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif. , Jan.
View HTML